SCHEMBL538420

SCHEMBL538420

CN(C)c1cccc(N=Nc2ccccc2)c1[C]=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.44
▸ MAPK1 P28482 5/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ TSHR P16473 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MYC P01106 1/20 0.43
▸ KMT2A Q03164 6/20 0.41
▸ MEN1 O00255 5/20 0.41
▸ NPC1 O15118 5/20 0.41
▸ RAB9A P51151 4/20 0.41
▸ ALPL P05186 1/20 0.41
▸ ALPI P09923 1/20 0.41
▸ ALPG P10696 1/20 0.41
▸ MAPT P10636 7/20 0.39
▸ POLB P06746 1/20 0.39
▸ CASP3 P42574 3/20 0.38
▸ SENP8 Q96LD8 3/20 0.38
▸ SENP7 Q9BQF6 3/20 0.38
▸ SENP6 Q9GZR1 3/20 0.38
▸ NSD2 O96028 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28313589 0.81 TDP1 (0.55) TDP1MAPK1ALDH1A1TSHRHSD17B10
SCHEMBL187588 0.81 TDP1 (0.55) TDP1MAPK1ALDH1A1TSHRHSD17B10
SCHEMBL30342247 0.81 TDP1 (0.55) TDP1MAPK1ALDH1A1TSHRHSD17B10
SCHEMBL29747008 0.79 MAPK1 (0.53) TDP1MAPK1ALDH1A1TSHRHSD17B10
Hydrogen Sulfide SCHEMBL28338492 0.79 TDP1 (0.53) TDP1MAPK1ALDH1A1TSHRHSD17B10
SCHEMBL3412053 0.77 MYC (0.54) TDP1MAPK1ALDH1A1TSHRHSD17B10
SCHEMBL133466 0.76 TDP1 (0.43) TDP1MAPK1ALDH1A1TSHRHSD17B10
Isothiocyanate SCHEMBL8352965 0.75 TDP1 (0.46) TDP1MAPK1ALDH1A1TSHRHSD17B10
SCHEMBL4252088 0.75 KMT2A (0.45) TDP1MAPK1ALDH1A1TSHRHSD17B10
SCHEMBL8619132 0.75 MEN1 (0.46) TDP1MAPK1ALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10829803-B2 Detection of nucleic acid targets using chemically reactive oligonucleotide probes DXTERITY DIAGNOSTICS INCORPORATED (US) 2020-11-10 — — US disclosed
US-20190106739-A1 CHEMICAL LIGATION DEPENDENT PROBE AMPLIFICATION (CLPA) DXTERITY DIAGNOSTICS INCORPORATED 2019-04-11 — — US disclosed
US-10066257-B2 Methods and compositions for detecting target nucleic acids DXTERITY DIAGNOSTICS INCORPORATED (US) 2018-09-04 — — US disclosed
US-9976177-B2 Chemical ligation dependent probe amplification (CLPA) DXTERITY DIAGNOSTICS INCORPORATED (US) 2018-05-22 — — US disclosed
US-20180030520-A1 METHODS AND COMPOSITIONS FOR DETECTING TARGET NUCLEIC ACIDS DXTERITY DIAGNOSTICS INCORPORATED 2018-02-01 — — US disclosed
US-9745616-B2 Methods and compositions for detecting target nucleic acids DXTERITY DIAGNOSTICS INCORPORATED (US) 2017-08-29 — — US disclosed
EP-2765205-B1 Chemical ligation dependent probe amplification (CLPA) DXTERITY DIAGNOSTICS INC (US) 2016-05-18 — — EP disclosed
EP-2710145-B1 METHODS AND COMPOSITIONS FOR DETECTING TARGET NUCLEIC ACIDS DXTERITY DIAGNOSTICS INC (US) 2015-12-09 — — EP disclosed
EP-2765205-A1 Chemical ligation dependent probe amplification (CLPA) DXTerity Diagnostics Incorporated (US) 2014-08-13 — — EP disclosed
US-20140171338-A1 METHODS AND COMPOSITIONS FOR DETECTING TARGET NUCLEIC ACIDS DXTERITY DIAGNOSTICS INCORPORATED (US) 2014-06-19 — — US disclosed
EP-2710145-A1 METHODS AND COMPOSITIONS FOR DETECTING TARGET NUCLEIC ACIDS Dxterity Diagnostics Incorporated (US) 2014-03-26 — — EP disclosed
EP-2677039-A2 Detection of nucleic acid targets using chemically reactive oligonucleotide probes Dxterity Diagnostics (US) 2013-12-25 — — EP disclosed
US-20130005594-A1 METHODS AND COMPOSITIONS FOR DETECTING TARGET NUCLEIC ACIDS DXTERITY DIAGNOSTICS INCORPORATED (US) 2013-01-03 — — US disclosed
WO-2012158967-A1 METHODS AND COMPOSITIONS FOR DETECTING TARGET NUCLEIC ACIDS DXTERITY DIAGNOSTICS INCORPORATED (US) 2012-11-22 — — WO disclosed
EP-2414544-A1 CHEMICAL LIGATION DEPENDENT PROBE AMPLIFICATION (CLPA) DXTerity Diagnostics Incorporated (US) 2012-02-08 — — EP disclosed
US-20100267585-A1 Chemical ligation dependent probe amplification (CLPA) DXTERITY DIAGNOSTICS 2010-10-21 — — US disclosed
WO-2010114599-A1 CHEMICAL LIGATION DEPENDENT PROBE AMPLIFICATION (CLPA) DX TERITY DIAGNOSTICS INC. (US) 2010-10-07 — — WO disclosed
EP-2021514-A2 DETECTION OF NUCLEIC ACID TARGETS USING CHEMICALLY REACTIVE OLIGONUCLEOTIDE PROBES Dxterity Diagnostics (US) 2009-02-11 — — EP disclosed
US-20080124810-A1 Detection of nucleic acid targets using chemically reactive oligonucleotide probes DXTERITY DIAGNOSTICS (US) 2008-05-29 — — US disclosed
WO-2007133703-A2 DETECTION OF NUCLEIC ACID TARGETS USING CHEMICALLY REACTIVE OLIGONUCLEOTIDE PROBES DXTERITY DIAGNOSTICS (US) 2007-11-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080124810-A1 Detection of nucleic acid targets using chemically reactive oligonucleotide probes POLRMT, LIG4, LIG3 TDP1 238/4885MAPK1 4778/4885ALDH1A1 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback